Literature DB >> 12684268

Inhibition of G protein-activated inwardly rectifying K+ channels by fluoxetine (Prozac).

Toru Kobayashi1, Kazuo Washiyama, Kazutaka Ikeda.   

Abstract

1. The effects of fluoxetine, a commonly used antidepressant drug, on G protein-activated inwardly rectifying K(+) channels (GIRK, Kir3) were investigated using Xenopus oocyte expression assays. 2. In oocytes injected with mRNAs for GIRK1/GIRK2, GIRK2 or GIRK1/GIRK4 subunits, fluoxetine reversibly reduced inward currents through the basal GIRK activity. The inhibition by fluoxetine showed a concentration-dependence, a weak voltage-dependence and a slight time-dependence with a predominant effect on the instantaneous current elicited by voltage pulses and followed by slight further inhibition. Furthermore, in oocytes expressing GIRK1/2 channels and the cloned Xenopus A(1) adenosine receptor, GIRK current responses activated by the receptor were inhibited by fluoxetine. In contrast, ROMK1 and IRK1 channels in other Kir channel subfamilies were insensitive to fluoxetine. 3. The inhibitory effect on GIRK channels was not obtained by intracellularly applied fluoxetine, and not affected by extracellular pH, which changed the proportion of the uncharged to protonated fluoxetine, suggesting that fluoxetine inhibits GIRK channels from the extracellular side. 4. The GIRK currents induced by ethanol were also attenuated in the presence of fluoxetine. 5. We demonstrate that fluoxetine, at low micromolar concentrations, inhibits GIRK channels that play an important role in the inhibitory regulation of neuronal excitability in most brain regions and the heart rate through activation of various G-protein-coupled receptors. The present results suggest that inhibition of GIRK channels by fluoxetine may contribute to some of its therapeutic effects and adverse side effects, particularly seizures in overdose, observed in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684268      PMCID: PMC1573762          DOI: 10.1038/sj.bjp.0705172

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  63 in total

Review 1.  The role of selective serotonin reuptake inhibitors in reducing alcohol consumption.

Authors:  C A Naranjo; D M Knoke
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

2.  Effects of antidepressants on the inward current mediated by 5-HT3 receptors in rat nodose ganglion neurones.

Authors:  P Fan
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

Review 3.  Comparison of the three mouse G-protein-activated K+ (GIRK) channels and functional couplings of the opioid receptors with the GIRK1 channel.

Authors:  K Ikeda; T Kobayashi; T Ichikawa; H Usui; S Abe; T Kumanishi
Journal:  Ann N Y Acad Sci       Date:  1996-10-31       Impact factor: 5.691

4.  Ethanol opens G-protein-activated inwardly rectifying K+ channels.

Authors:  T Kobayashi; K Ikeda; H Kojima; H Niki; R Yano; T Yoshioka; T Kumanishi
Journal:  Nat Neurosci       Date:  1999-12       Impact factor: 24.884

5.  A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation.

Authors:  N Patil; D R Cox; D Bhat; M Faham; R M Myers; A S Peterson
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

6.  Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel.

Authors:  Y Kubo; E Reuveny; P A Slesinger; Y N Jan; L Y Jan
Journal:  Nature       Date:  1993-08-26       Impact factor: 49.962

7.  Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac).

Authors:  J García-Colunga; J N Awad; R Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

8.  Functional characterization of an endogenous Xenopus oocyte adenosine receptor.

Authors:  Toru Kobayashi; Kazutaka Ikeda; Toshiro Kumanishi
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

9.  Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1.

Authors:  B H Choi; J S Choi; S H Yoon; D J Rhie; D S Min; Y H Jo; M S Kim; S J Hahn
Journal:  Neuropharmacology       Date:  2001-09       Impact factor: 5.250

10.  Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics.

Authors:  T Stanton; C Bolden-Watson; B Cusack; E Richelson
Journal:  Biochem Pharmacol       Date:  1993-06-09       Impact factor: 5.858

View more
  27 in total

Review 1.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

2.  A novel mitochondrial K(ATP) channel assay.

Authors:  Andrew P Wojtovich; David M Williams; Marcin K Karcz; Coeli M B Lopes; Daniel A Gray; Keith W Nehrke; Paul S Brookes
Journal:  Circ Res       Date:  2010-02-25       Impact factor: 17.367

3.  Selective serotonin reuptake inhibitors facilitate ANO6 (TMEM16F) current activation and phosphatidylserine exposure.

Authors:  Hyun Jong Kim; Ikhyun Jun; Jae Seok Yoon; Jinsei Jung; Yung Kyu Kim; Woo Kyung Kim; Byung Joo Kim; Jaewoo Song; Sung Joon Kim; Joo Hyun Nam; Min Goo Lee
Journal:  Pflugers Arch       Date:  2015-01-30       Impact factor: 3.657

Review 4.  Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel.

Authors:  Andrew P Wojtovich; C Owen Smith; Cole M Haynes; Keith W Nehrke; Paul S Brookes
Journal:  Biochim Biophys Acta       Date:  2013-01-02

5.  Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.

Authors:  Alexander M Kleschevnikov; Jessica Yu; Jeesun Kim; Larisa V Lysenko; Zheng Zeng; Y Eugene Yu; William C Mobley
Journal:  Neurobiol Dis       Date:  2017-03-22       Impact factor: 5.996

6.  Interaction of paroxetine with mitochondrial proteins mediates neuroprotection.

Authors:  Joseph P Steiner; Muznabanu Bachani; Brett Wolfson-Stofko; Myoung-Hwa Lee; Tongguang Wang; Tonguang Wang; Guanhan Li; Wenxue Li; David Strayer; Norman J Haughey; Avindra Nath
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 7.  A pharmacological analysis of mice with a targeted disruption of the serotonin transporter.

Authors:  Meredith A Fox; Anne M Andrews; Jens R Wendland; Klaus-Peter Lesch; Andrew Holmes; Dennis L Murphy
Journal:  Psychopharmacology (Berl)       Date:  2007-08-22       Impact factor: 4.530

8.  Kir6.2 is not the mitochondrial KATP channel but is required for cardioprotection by ischemic preconditioning.

Authors:  Andrew P Wojtovich; William R Urciuoli; Shampa Chatterjee; Aron B Fisher; Keith Nehrke; Paul S Brookes
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

Review 9.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

10.  Pregnenolone sulfate potentiates the inwardly rectifying K channel Kir2.3.

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.